Authors:
NEPHEW KP
SHEELER CQ
DUDLEY MD
GORDON S
NAYFIELD SG
KHAN SA
Citation: Kp. Nephew et al., STUDIES OF DEHYDROEPIANDROSTERONE (DHEA) WITH THE HUMAN ESTROGEN-RECEPTOR IN YEAST, Molecular and cellular endocrinology, 143(1-2), 1998, pp. 133-142
Authors:
BALLARDBARBASH R
POTOSKY AL
HARLAN LC
NAYFIELD SG
KESSLER LG
Citation: R. Ballardbarbash et al., FACTORS ASSOCIATED WITH SURGICAL AND RADIATION-THERAPY FOR EARLY-STAGE BREAST-CANCER IN OLDER WOMEN, Journal of the National Cancer Institute, 88(11), 1996, pp. 716-726
Authors:
KELLOFF GJ
CROWELL JA
HAWK ET
STEELE VE
LUBET RA
BOONE CW
COVEY JM
DOODY LA
OMENN GS
GREENWALD P
HONG WK
PARKINSON DR
BAGHERI D
BAXTER GT
BLUNDEN M
DOELTZ MK
EISENHAUER KM
JOHNSON K
KNAPP GG
LONGFELLOW DG
MALONE WF
NAYFIELD SG
SEIFRIED HE
SWALL LM
SIGMAN CC
Citation: Gj. Kelloff et al., STRATEGY AND PLANNING FOR CHEMOPREVENTIVE DRUG DEVELOPMENT - CLINICALDEVELOPMENT PLANS-II, Journal of cellular biochemistry, 1996, pp. 54-71
Authors:
KELLOFF GJ
CROWELL JA
HAWK ET
STEELE VE
LUBET RA
BOONE CW
COVEY JM
DOODY LA
OMENN GS
GREENWALD P
HONG WK
PARKINSON DR
BAGHERI D
BAXTER GT
BLUNDEN M
DOELTZ MK
EISENHAUER KM
JOHNSON K
KNAPP GG
LONGFELLOW DG
MALONE WF
NAYFIELD SG
SEIFRIED HE
SWALL LM
SIGMAN CC
Citation: Gj. Kelloff et al., CLINICAL DEVELOPMENT PLANS FOR CANCER CHEMOPREVENTIVE AGENTS, Journal of cellular biochemistry, 1996, pp. 72-321
Citation: Sg. Nayfield, ETHICAL AND SCIENTIFIC CONSIDERATIONS FOR CHEMOPREVENTION RESEARCH INCOHORTS AT GENETIC RISK FOR BREAST-CANCER, Journal of cellular biochemistry, 1996, pp. 123-130
Authors:
KELLOFF GJ
BOONE CW
CROWELL JA
NAYFIELD SG
HAWK E
STEELE VE
LUBET RA
SIGMAN CC
Citation: Gj. Kelloff et al., STRATEGIES FOR PHASE-II CANCER CHEMOPREVENTION TRIALS - CERVIX, ENDOMETRIUM, AND OVARY, Journal of cellular biochemistry, 1995, pp. 1-9
Citation: Ml. Brown et al., ADJUVANT THERAPY FOR STAGE-III COLON-CANCER - ECONOMICS RETURNS TO RESEARCH AND COST-EFFECTIVENESS OF TREATMENT, Journal of the National Cancer Institute, 86(6), 1994, pp. 424-430
Authors:
NAYFIELD SG
BONGIOVANNI GC
ALCIATI MH
FISCHER RA
BERGNER L
Citation: Sg. Nayfield et al., STATUTORY REQUIREMENTS FOR DISCLOSURE OF BREAST-CANCER-TREATMENT ALTERNATIVES, Journal of the National Cancer Institute, 86(16), 1994, pp. 1202-1208
Authors:
JOHNSON TP
FORD L
WARNECKE RB
NAYFIELD SG
KALUZNY A
CUTTER G
GILLINGS D
SONDIK E
OZER H
Citation: Tp. Johnson et al., EFFECT OF A NATIONAL-CANCER-INSTITUTE CLINICAL-ALERT ON BREAST-CANCERPRACTICE PATTERNS, Journal of clinical oncology, 12(9), 1994, pp. 1783-1788
Authors:
FEUER EJ
FREY CM
BRAWLEY OW
NAYFIELD SG
CUNNINGHAM JB
GELLER NL
BOSL GJ
KRAMER BS
Citation: Ej. Feuer et al., AFTER A TREATMENT BREAKTHROUGH - A COMPARISON OF TRIAL AND POPULATION-BASED DATA FOR ADVANCED TESTICULAR CANCER, Journal of clinical oncology, 12(2), 1994, pp. 368-377